April 13, 2025 at 3:15 PM
#ESCMIDGlobal #FOMO…. Watching online the amazing @elisemitri.bsky.social and thanks to @cmicomms.bsky.social for publishing this work! Not missing another #ESCMIDGlobal!!
Congrats to @elisemitri.bsky.social, @trubianojason.bsky.social et al for their great work on safely delabeling patients with #penicillinallergy. Elise presenting their prospective, pharmacist-led program live at #ESCMIDGlobal
#IDSky #PharmSky #openacess
www.cmi-comms.com/article/S295...
#IDSky #PharmSky #openacess
www.cmi-comms.com/article/S295...
April 13, 2025 at 12:11 PM
#ESCMIDGlobal #FOMO…. Watching online the amazing @elisemitri.bsky.social and thanks to @cmicomms.bsky.social for publishing this work! Not missing another #ESCMIDGlobal!!
We are happy to be expanding our reach into the wide open Bluesky!
Be sure to follow us for all updates on our Society and on the upcoming #ESCMIDGlobal 2025.
#IDsky #medsky
Be sure to follow us for all updates on our Society and on the upcoming #ESCMIDGlobal 2025.
#IDsky #medsky
November 12, 2024 at 1:06 PM
We are happy to be expanding our reach into the wide open Bluesky!
Be sure to follow us for all updates on our Society and on the upcoming #ESCMIDGlobal 2025.
#IDsky #medsky
Be sure to follow us for all updates on our Society and on the upcoming #ESCMIDGlobal 2025.
#IDsky #medsky
The most anticipated RCT in ID
🔥SNAP RCT🔥The largest RCT 2 date in SA bactermia
N:1341
Cefazolin Vs ASPs ((flu)cloxacillin) for MSSA bacteremia
Cefazolin is non-inferior (90d mortality)& less AKI than ASPs
A practice-changer RCT that must change the guidelines
#ESCMIDGlobal #IDSky
🔥SNAP RCT🔥The largest RCT 2 date in SA bactermia
N:1341
Cefazolin Vs ASPs ((flu)cloxacillin) for MSSA bacteremia
Cefazolin is non-inferior (90d mortality)& less AKI than ASPs
A practice-changer RCT that must change the guidelines
#ESCMIDGlobal #IDSky
April 12, 2025 at 3:14 PM
Just arriving at #ESCMIDglobal. Looking forward to catching up with colleagues from all around the world. #IDsky
April 11, 2025 at 12:17 PM
Just arriving at #ESCMIDglobal. Looking forward to catching up with colleagues from all around the world. #IDsky
Having a blast at #ESCMIDGlobal 2025 #Vienna
April 13, 2025 at 8:52 PM
Having a blast at #ESCMIDGlobal 2025 #Vienna
We are happy to announce that we received once again over 7000 abstract submissions for #ESCMIDGlobal this year. A big thank you to all who submitted to be part of our congress and we look forward to seeing your incredible research on display in Vienna in April! #IDSky #clinmicro
November 30, 2024 at 6:41 AM
Taking a break from talking about #SNAPtrial to work on a new collaboration
#IDSky #ESCMIDglobal
@steventong.bsky.social
#IDSky #ESCMIDglobal
@steventong.bsky.social
April 14, 2025 at 3:20 PM
Taking a break from talking about #SNAPtrial to work on a new collaboration
#IDSky #ESCMIDglobal
@steventong.bsky.social
#IDSky #ESCMIDglobal
@steventong.bsky.social
Listening to @marionkoopmans.bsky.social giving the ESCMID excellence award lecture “Towards pandemic prevention, moonshot or utopia?” at #ESCMIDGlobal
@escmid.bsky.social
@escmid.bsky.social
April 14, 2025 at 2:22 PM
Listening to @marionkoopmans.bsky.social giving the ESCMID excellence award lecture “Towards pandemic prevention, moonshot or utopia?” at #ESCMIDGlobal
@escmid.bsky.social
@escmid.bsky.social
Excited that at #ESCMIDGlobal 2025, SNAP trial results for PSSA and MSSA silo backbone domains will be presented.
What's more it's a new format 2 hour session! 3 trials (SNAPx2, CLOCEBA), with expert led & audience discussion.
Sat April 12 16:15 - 18:15 Hall 13
Drinks after
@escmid.bsky.social
What's more it's a new format 2 hour session! 3 trials (SNAPx2, CLOCEBA), with expert led & audience discussion.
Sat April 12 16:15 - 18:15 Hall 13
Drinks after
@escmid.bsky.social
March 7, 2025 at 5:06 AM
Excited that at #ESCMIDGlobal 2025, SNAP trial results for PSSA and MSSA silo backbone domains will be presented.
What's more it's a new format 2 hour session! 3 trials (SNAPx2, CLOCEBA), with expert led & audience discussion.
Sat April 12 16:15 - 18:15 Hall 13
Drinks after
@escmid.bsky.social
What's more it's a new format 2 hour session! 3 trials (SNAPx2, CLOCEBA), with expert led & audience discussion.
Sat April 12 16:15 - 18:15 Hall 13
Drinks after
@escmid.bsky.social
My final #ESCMIDGlobal session for Sunday is Tuberculosis: where are we now and where should we be.
April 13, 2025 at 1:43 PM
My final #ESCMIDGlobal session for Sunday is Tuberculosis: where are we now and where should we be.
The next #Communicable episode drops Monday, 19 May! CMI Comms editors @marcbonten.bsky.social @gurujosh.bsky.social @erinmccreary.bsky.social & @dremilymcd.bsky.social discuss key latebreaker trials presented at #ESCMIDGlobal & whether they should change your practice 🔍
#IDSky #MedSky #clinmicro
#IDSky #MedSky #clinmicro
May 15, 2025 at 10:45 AM
The next #Communicable episode drops Monday, 19 May! CMI Comms editors @marcbonten.bsky.social @gurujosh.bsky.social @erinmccreary.bsky.social & @dremilymcd.bsky.social discuss key latebreaker trials presented at #ESCMIDGlobal & whether they should change your practice 🔍
#IDSky #MedSky #clinmicro
#IDSky #MedSky #clinmicro
@msf.ca is at #ESCMIDGlobal talking about #AMR!
Pass by our booth to know more about our work!
#Viena @escmid.bsky.social
Pass by our booth to know more about our work!
#Viena @escmid.bsky.social
April 13, 2025 at 12:01 PM
@msf.ca is at #ESCMIDGlobal talking about #AMR!
Pass by our booth to know more about our work!
#Viena @escmid.bsky.social
Pass by our booth to know more about our work!
#Viena @escmid.bsky.social
ModMedMicro at #ESCMIDGlobal (well nearly everyone!)
April 14, 2025 at 2:08 PM
ModMedMicro at #ESCMIDGlobal (well nearly everyone!)
🤩 Excited to hear @dianeashiru.bsky.social talk about trying to measure quality of antibiotic use. @escmid.bsky.social #ESCMIDglobal #ESCMID2025
April 13, 2025 at 7:07 AM
🤩 Excited to hear @dianeashiru.bsky.social talk about trying to measure quality of antibiotic use. @escmid.bsky.social #ESCMIDglobal #ESCMID2025
Congratulations to @angelahuttner.bsky.social for your great achievements with your journal and podcast 🥳
#ESCMIDGlobal
#ESCMIDGlobal
April 12, 2025 at 4:49 PM
Congratulations to @angelahuttner.bsky.social for your great achievements with your journal and podcast 🥳
#ESCMIDGlobal
#ESCMIDGlobal
The first #Communicable & #Breakpoints collaboration episode drops Mon 5 May! Hosts @angelahuttner.bsky.social
& @erinmccreary.bsky.social interview SNAP trial investigators, @steventong.bsky.social & Joshua Davis, on the results shared at #ESCMIDGlobal 2025. #IDSky #clinmicro
@sidpharm.bsky.social
& @erinmccreary.bsky.social interview SNAP trial investigators, @steventong.bsky.social & Joshua Davis, on the results shared at #ESCMIDGlobal 2025. #IDSky #clinmicro
@sidpharm.bsky.social
April 30, 2025 at 9:59 AM
The first #Communicable & #Breakpoints collaboration episode drops Mon 5 May! Hosts @angelahuttner.bsky.social
& @erinmccreary.bsky.social interview SNAP trial investigators, @steventong.bsky.social & Joshua Davis, on the results shared at #ESCMIDGlobal 2025. #IDSky #clinmicro
@sidpharm.bsky.social
& @erinmccreary.bsky.social interview SNAP trial investigators, @steventong.bsky.social & Joshua Davis, on the results shared at #ESCMIDGlobal 2025. #IDSky #clinmicro
@sidpharm.bsky.social
My practice just changed. #ESCMIDGlobal
Dr Steven Tong presents data on Penicillin vs (Flu)Cloxacillin for penicillin sensitive S.aureus.
1. Penicillin is non-inferior.
2. Rate of AKI roughly half in Penicillin group.
3. More pts in Penicillin group changed Rx - why?
#ESCMIDGlobal
1. Penicillin is non-inferior.
2. Rate of AKI roughly half in Penicillin group.
3. More pts in Penicillin group changed Rx - why?
#ESCMIDGlobal
April 12, 2025 at 3:14 PM
My practice just changed. #ESCMIDGlobal
😁😁😁 Great to make new connections and see familiar faces @escmid.bsky.social #ESCMIDglobal #ESCMID2025 #ESCMIDglobal2025
@dianeashiru.bsky.social @erinmccreary.bsky.social
@dianeashiru.bsky.social @erinmccreary.bsky.social
April 14, 2025 at 2:32 PM
😁😁😁 Great to make new connections and see familiar faces @escmid.bsky.social #ESCMIDglobal #ESCMID2025 #ESCMIDglobal2025
@dianeashiru.bsky.social @erinmccreary.bsky.social
@dianeashiru.bsky.social @erinmccreary.bsky.social
Given discussions at I had at #ESCMIDGlobal, it might be useful for new researchers to know how a journal editor screens submissions (obviously this is my approach and so it might differ for others).
April 15, 2025 at 1:24 PM
Given discussions at I had at #ESCMIDGlobal, it might be useful for new researchers to know how a journal editor screens submissions (obviously this is my approach and so it might differ for others).
April 12, 2025 at 2:44 PM